Steven O’Day, MD
The John Wayne Cancer Institute
Dr. O’Day, MD has been at the forefront of new drug development in melanoma and most recently played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. Dr. O’Day has been a principal investigator on over 100 clinical trials including several large, international phase 3 trials. Dr. O’Day is the Professor of Medical Oncology, Director of Immuno-Oncology, Director of Research at The John Wayne Cancer Institute at Providence St. John’s Health Center. Dr. O’Day received his medical training at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston.
Caroline Robert, MD, PhD
Dr. Robert is a scientist of international renown in the clinical and translational research of melanoma and the cutaneous side effects of new, targeted chemotherapies. She is head of the Dermatology Unit at the Institut Gustave-Roussy, Paris, France and previously was medical director for Johnson & Johnson Consumer Europe. Dr. Robert received her medical degree at the Cochin Port-Royal School of Medicine, Paris, followed by French Board Certification in dermatology. She completed a research fellowship at Harvard University and a PhD in cancer immunology and immunotherapy.
Triple Negative Breast Cancer
Joyce O’Shaughnessy, MD
Texas Oncology | Baylor Sammons Cancer Center | US Oncology Network
Dr. O’Shaughnessy is the Celebrating Women Chair in Breast Cancer Research at Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for The US Oncology Network. She specializes in breast medical oncology. She is a Diplomate of the American Board of Internal Medicine. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She received her M.D. from Yale University Medical School.